ArticleCurrent neuropharmacology2026
Article in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic cerebral ischemia (CCI) induces hippocampal neuronal injury, with mitochondrial dysfunction emerging as a pivotal pathological driver of ischemic brain damage. Enhancing mitochondrial biogenesis (MB) represents a promising reparative strategy to restore neuronal homeostasis. Rhodiola sacra (RS), a traditional Tibetan herb, exhibits neuroprotective potential against ischemic injury; however, its underlying mechanisms, particularly its association with MB, remain unclear. This study aims to investigate the protective effects of RS on neuronal apoptosis and mitochondrial dysfunction in CCI rats and oxygen-glucose deprivation (OGD)-exposed cells, with a focus on elucidating the role of SIRT1 in mediating these effects.
methodsThe CCI rat model was established through bilateral common carotid artery occlusion. Spatial learning and memory abilities were evaluated using the Morris water maze. Hippocampal neuronal apoptosis was assessed via TUNEL staining, and mitochondrial damage was examined using transmission electron microscopy. Flow cytometry was employed to detect cell apoptosis, mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) levels. Immunofluorescence staining was used to visualize the mitochondrial permeability transition pore (mPTP). Intracellular ATP levels were measured using a luminol-based chemiluminescence assay, and mitochondrial DNA (mtDNA) content was quantified by qPCR. Additionally, small interfering RNA (siRNA) was utilized to verify the critical role of SIRT1 in mediating the protective effects.
resultsRS significantly improved spatial learning and memory, attenuated hippocampal neuronal apoptosis, and increased mitochondrial content in CCI rats. In SH-SY5Y cells exposed to OGD, salidroside, a key active component of RS, reduced apoptosis and restored mitochondrial function, as evidenced by elevated MMP, ATP, and mtDNA levels, along with suppressed ROS and mPTP activity. Mechanistically, salidroside upregulated SIRT1 expression, which correlated with enhanced MB markers. Notably, inhibition of SIRT1 abolished the anti-apoptotic effects and MB activation induced by salidroside. DISCUSSION: These findings highlight RS as a promising therapeutic agent for ischemic brain injury, targeting SIRT1 to restore MB.
conclusionRS mitigates neuronal apoptosis and mitochondrial dysfunction in CCI through SIRT1- dependent MB activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.